Antibody generation services: choosing between animal, display and single B cell platforms, how antibody discovery platforms and any antibody discovery service or antibody discovery services offering differ once antibody discovery has produced a panel, what phage display for antibody discovery reaches through a phage display library or phage display antibody library and other antibody libraries, what discovery antibodies still owe in validation, what an antibody platform commits you to, and what antibody services should stage before a lead is chosen

Choosing the platform

1. Immunisation and hybridoma. The classical route gives affinity-matured antibodies against native epitopes and works well for immunogenic targets. It is slower, depends on an animal responding, and yields a hybridoma whose sequence you should insist on having so the reagent survives the freezer.
2. Phage and yeast display. Display screens very large libraries quickly and in vitro, so it handles toxic and non-immunogenic targets and gives fine control over selection conditions. Binders come out as sequences, which is convenient, but affinity maturation is a separate engineered step rather than a gift from the immune system.
3. Single B cell screening. Sequencing paired chains from individual B cells of an immunised animal combines native pairing with direct sequence output. It is the most expensive route and the one that most reliably gives renewable, sequenced leads from a real immune response.
4. Selection pressure is where you steer. Whatever the platform, what you find is what you selected for. Counter-selection against close homologues, selection at the pH or in the buffer the application uses, and screening in the assay format all change the leads. Specify these rather than leaving them to the provider's default.
5. Stage the contract at the first lead. Break the project at the point where leads exist and are characterised, before any engineering or production. That is the natural decision point, and a contract without it commits you to spending on a campaign that may have found nothing useful.

What you should own

Insist on the variable region sequences for every lead you pay to characterise. A sequence is reproducible anywhere and forever; a clone in a provider's freezer is a dependency and a single point of failure.

Clarify the position on background intellectual property in the platform itself, particularly for display libraries, since some carry downstream obligations that only become visible when the programme advances.

Characterisation before you commit

Ask for affinity measured by a stated method, specificity against a named counter-screen panel, cross-reactivity against the species you will work in, and behaviour in the intended assay format. A lead with only a binding signal on a plate is a candidate, not a result.

Developability screening matters if the antibody is ever going to be produced at scale: expression level, aggregation propensity and stability. Finding these problems after lead selection is a common and avoidable setback.

Common questions

What is the difference between antibody generation and antibody production?

Generation is discovering binders against a target; production is making more of an antibody that already exists. Generation projects are discovery work with real failure risk, which is why they should be staged.

Which platform should I choose?

Hybridoma for immunogenic targets where affinity matters and budget is limited; display for toxic, conserved or non-immunogenic targets and where selection control matters; single B cell where you want native pairing and sequenced leads and can afford it.

Can a generation campaign fail?

Yes, and it is the reason to stage the contract at the first characterised lead. Difficult targets, highly conserved epitopes and poor immunogens all produce campaigns with no usable binder.

Do I get the antibody sequence?

Only if the contract says so. Ask for the variable region sequences of every lead you pay to characterise, because that is what makes the reagent renewable independently of the provider.

Browse by service class

• Compare Gene synthesis on advertised prices